The Trump administration launched the Medicare GLP-1 Bridge program, setting the cost for three weight-loss medications at $50 per month: Wegovy, a KwikPen version of Zepbound (tirzepatide), and Foundayo (orforglipron). The initiative targets affordability as GLP-1 use expands among older Americans with obesity. Clinical experts highlighted that while eligibility does not guarantee benefit, evidence for GLP-1 use in the 60-and-older population remains limited, with older adults often underrepresented in early pivotal trials. Researchers and clinicians emphasized that older patients are heterogeneous, with differences in frailty, polypharmacy, and vulnerability to side effects. The policy shift is likely to increase prescribing volume and intensify the need for age-stratified safety and effectiveness data in real-world settings.